Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(28 sites)
United States
Medical Dermatology Specialists, Phoenix, Arizona Mayo Clinic Arizona, Phoenix, Arizona University of California, San Diego, La Jolla, California University of California, Los Angeles, Los Angeles, California UCSF, Helen Diller Family Comprehensive Cancer Center, San Francisco, California University of Colorado Cancer Center School of Medicine, Aurora, Colorado Mayo Clinic Florida, Jacksonville, Florida University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida Moffitt Cancer Center, Tampa, Florida University of Chicago, Chicago, Illinois Dana Farber Cancer Institute, Boston, Massachusetts University of Michigan, Ann Arbor, Michigan Mayo Clinic Rochester, Rochester, Minnesota Washington University in St. Louis, St Louis, Missouri Columbia University Medical Center, New York, New York Rochester Dermatologic Surgery, New York, New York University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina Duke University, Durham, North Carolina University of Cincinnati, Cincinnati, Ohio The Cleveland Clinic Foundation, Cleveland, Ohio The Ohio State University Comprehensive Cancer Center, Columbus, Ohio Oregon Health and Science University, Portland, Oregon University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania University of Tennessee Medical Center at Knoxville, Knoxville, Tennessee University of Texas Southwestern, Dallas, Texas MD Anderson Cancer Center, Houston, Texas Inova Schar Cancer Institute, Fairfax, Virginia VCU Massey Cancer Center, Richmond, Virginia